Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection.
The design of clinical trials for new antiretroviral agents poses unique challenges, given the availability of highly active antiretroviral therapy (HAART). These challenges include the selection of appropriate populations, the methods used to partition the effects of the study drug under observation from those of the other concurrently administered medications in early studies, performance of dose-ranging studies for disease states in which suboptimal drug exposure may lead to the development of viral resistance that limits future treatment options, and the need to fulfill the obligations of international regulatory agencies. Throughout, science and ethics are tightly woven elements in study designs for antiretroviral drug trials. Fast-track drug approval status and successful lobbying by advocates for patients with acquired immunodeficiency syndrome aimed at the US Food and Drug Administration, the National Institutes of Health, the Centers for Disease Control and Prevention, university teaching centers, pharmaceutical companies, and members of Congress undoubtedly contributed to the development and swift regulatory approvals of the 17 antiretroviral medications now available in the United States for the treatment of human immunodeficiency virus infection.
Feinberg
Judith
J
Department of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Japour
Anthony J
AJ
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D035843:Biomedical Research; D002986:Clinical Trials as Topic / Q000941:ethics* / Q000379:methods; D017321:Clinical Trials, Phase I as Topic / Q000941:ethics / Q000379:methods; D017322:Clinical Trials, Phase II as Topic / Q000941:ethics / Q000379:methods; D017326:Clinical Trials, Phase III as Topic / Q000941:ethics / Q000379:methods; D015507:Drugs, Investigational / Q000627:therapeutic use*; D026690:Ethics, Clinical; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D012107:Research Design
D019380:Anti-HIV Agents; D015507:Drugs, Investigational